- Home
- INGR vs EXEL Comparison
INGR vs EXEL Comparison
Compare INGR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INGR
- EXEL
- Stock Information
- Founded
- INGR 1906
- EXEL 1994
- Country
- INGR United States
- EXEL United States
- Employees
- INGR N/A
- EXEL N/A
- Industry
- INGR Packaged Foods
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INGR Consumer Staples
- EXEL Health Care
- Exchange
- INGR Nasdaq
- EXEL Nasdaq
- Market Cap
- INGR 8.7B
- EXEL 7.4B
- IPO Year
- INGR 1997
- EXEL 2000
- Fundamental
- Price
- INGR $134.72
- EXEL $29.06
- Analyst Decision
- INGR Buy
- EXEL Buy
- Analyst Count
- INGR 6
- EXEL 14
- Target Price
- INGR $137.33
- EXEL $29.43
- AVG Volume (30 Days)
- INGR 347.6K
- EXEL 2.0M
- Earning Date
- INGR 11-05-2024
- EXEL 10-29-2024
- Dividend Yield
- INGR 2.37%
- EXEL N/A
- EPS Growth
- INGR 14.14
- EXEL 128.01
- EPS
- INGR 9.79
- EXEL 1.14
- Revenue
- INGR $7,714,000,000.00
- EXEL $2,013,976,000.00
- Revenue This Year
- INGR N/A
- EXEL $14.25
- Revenue Next Year
- INGR $0.52
- EXEL $0.48
- P/E Ratio
- INGR $13.81
- EXEL $25.44
- Revenue Growth
- INGR N/A
- EXEL 17.48
- 52 Week Low
- INGR $89.54
- EXEL $18.64
- 52 Week High
- INGR $138.37
- EXEL $29.75
- Technical
- Relative Strength Index (RSI)
- INGR 51.83
- EXEL 70.34
- Support Level
- INGR $132.85
- EXEL $26.06
- Resistance Level
- INGR $136.98
- EXEL $26.90
- Average True Range (ATR)
- INGR 1.58
- EXEL 0.81
- MACD
- INGR -0.22
- EXEL 0.32
- Stochastic Oscillator
- INGR 38.56
- EXEL 84.94
About INGR Ingredion Incorporated
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company has two main product lines: specialty and core ingredients. Specialty ingredients includes starch-based texturizers, natural alternative sweeteners such as stevia, and plant proteins for alternative dairy and snacks. Core ingredients includes sweeteners, such as high-fructose corn syrup, and commodity starches, such as those used for sustainable packaging.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.